Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Key Takeaways KROS is set to report Q4 results, with investors focused on pipeline progress over limited license revenues.Rinvatercept advanced in DMD with phase I data and orphan drug tag; phase II start planned for 2026.Takeda deal on elritercept triggered $10M milestone as phase III RENEW study dosed first patient.We expect investors to focus on pipeline updates when Keros Therapeutics (KROS) reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6 ...